A hallmark of human cancer is heterogeneity, reflecting the complex series of changes resulting in the activation of oncogenes coupled with inactivation of tumor suppressor genes. Breast cancer is no exception and indeed, many studies have revealed considerable complexity and heterogeneity in the population of primary breast tumors and substantial changes in a recurrent breast tumor that has acquired metastatic properties and drug resistance. We have made use of a Myc-inducible transgenic mouse model of breast cancer in which elimination of Myc activity following tumor development initially leads to a regression of a subset of tumors generally followed by de novo Mycindependent growth. We have observed that tumors that grow independent of Myc expression have gene profiles that are distinct from the primary tumors with characteristics indicative of an epithelial-mesenchymal transition (EMT) phenotype. Phenotypic analyses of Myc-independent tumors confirm the acquisition of an EMT phenotype suggested to be associated with invasive and migratory properties in human cancer cells. Further genomic analyses reveal mouse mammary tumors growing independent of myc have a higher probability of exhibiting a gene signature similar to that observed for human 'tumorinitiating' cells. Collectively, the data reveal genetic alterations that underlie tumor progression and an escape from Myc-dependent growth in a transgenic mouse model that can provide insights to what occurs in human cancers as they acquire drug resistance and metastatic properties.
Introduction
Human cancer, including breast cancer, is characterized by genetic complexity reflecting the acquisition of multiple mutations, amplifications, deletions and gene arrangements over a period of time. This heterogeneity is manifested in the primary tumors that exhibit considerable patient-to-patient variation that determines disease outcome and response to therapies as well as in the recurrent tumors that may additionally acquire the ability to metastasize to distant organs. Recent genome-scale studies of copy number variation and large-scale DNA sequencing efforts have provided direct evidence for this complexity (Sjoblom et al., 2006; Mullighan et al., 2007; Weir et al., 2007; Ding et al., 2008 Ding et al., , 2010 . It has become increasingly apparent that heterogeneity is also observed at the pathological level where the acquisition of certain histological features, such as those indicative of epithelial-mesenchymal transition (EMT), are often associated with more invasive cancer cells (Thiery, 2002; Thiery et al., 2009 ). An ability to model the complexity that gives rise to tumor heterogeneity is thus essential to understanding the oncogenic process and would enable the development of additional therapeutics to target the more aggressive cancer cells that evade conventional therapy.
Mouse models genetically engineered to explore the concept of oncogene addiction have guided our understanding of the genetic complexity underlying the progression of cancers. Prior work using the transgenic mouse models that conditionally overexpress the MYC oncogene has shown that inactivation of MYC can be sufficient to induce sustained tumor regression. Particularly in the lymphomas, islet cell tumors and skin tumors, withdrawal of MYC expression resulted in rapid tumor cell elimination through apoptosis (Pelengaris et al., 2002) . Similarly, MYC inactivation in osteogenic sarcoma resulted in terminal differentiation of tumor cells into mature bone cells resulting in cells that no longer have tumorgenic potential (Jain et al., 2002) . Although tumor initiation and progression in these systems appeared to be dependent on a single oncogenic event, more recent mouse models of MYCinduced hepatocellular carcinomas and mammary adenocarcinomas have exhibited a more complex situation apparently reflecting the action of multiple oncogenic events (D'Cruz et al., 2001; Boxer et al., 2004; Shachaf et al., 2004; Moody et al., 2005) . In these studies, inactivation of the oncogene resulted in regression of only a subset of the tumors. Tumors that initially regressed, showing a dependence on a specific oncogenic pathway, generally recurred exhibiting acquired resistance to pathway inhibition similar to what is observed during the course of human cancers. Additional studies using models that combine inducible Myc and Ras oncogenes have described further complexity with evidence of a hierarchy of oncogene dependence (Podsypanina et al., 2008) . The evident heterogeneity observed in these transgenic mice that conditionally overexpress an oncogene or oncogenes with respect to dependency on the initiating event suggests that these models can serve to reveal the complexities of the oncogenic process.
A particularly powerful approach to the study of genomic complexities that underlie these complex phenotypes has been the use of whole-genome expression analyses. Our previous work has made use of patterns of gene expression, as well as patterns of pathway activity revealed using signatures of pathway activation, to identify heterogeneity of tumors within mouse models (Andrechek et al., 2009) . We have further explored this heterogeneity, now in the context of the genomic alterations that occur to allow tumors to lose dependence on the initial oncogene activating event similar to how human cancers may acquire drug resistance.
Results

Genomic analysis of primary and Myc-independent tumors
The transgenic line mouse mammary tumor virus (MMTV)-rtTA (MTB) carries the reverse tetracyclinedependent transcriptional activator, rtTA, under the control of the MMTV. When mated to mice carrying the c-MYC transgene fused to a tetracycline-dependent promoter (TetO-Myc) (TOM), bitransgenic animals (MTB/TOM) are produced in which Myc is induced in the presence of doxycycline, resulting in the development of mammary adenocarcinomas with 100% penetrance. Tumors that develop are heterogeneneous since previous work has shown that upon withdrawal of doxycycline, approximately half of the adenocarcinomas regressed whereas the remaining half persisted independent of MYC expression (Boxer et al., 2004) .
We induced 35 mice with doxycycline and consistent with previous observations, doxycycline-administered MTB/TOM developed mammary tumors with a mean latency of 21.8 weeks (D'Cruz et al., 2001; Boxer et al., 2004) . From these 35 mice, we observed a total of 43 tumors. Upon withdrawal of doxycycline, 17 out of 43 (40%) tumors regressed to a nonpalpable state whereas the remaining 26 tumors (60%) showed variable degrees of regression, but did not reach a nonpalpable state (Figure 1b) . Tumors that regressed to a nonpalpable state recurred within 1-6 months and mice were euthanized when tumors reached 41 cm 3 . Among the tumors that did not reach a nonpalpable state, 16/43 (37%) tumors showed variable degrees of regression (from 490% regression where the tumor was barely palpable to o10% reduction in tumor volume) and resumed growth within 1-2 months. The remaining 10/43 tumors (23%) showed no signs of regression. Among the tumors that showed no signs of regression, one tumor appeared to remain dormant, whereas the rest of the tumors continued to grow. As an approach to the analysis of the genomic changes that might underlie the differential outcome following elimination of Myc, we utilized genome-scale gene expression analysis. We assessed gene expression profiles on Affymetrix 430A.2 (Affymetrix, Santa Clara, CA, USA) gene expression arrays of 37 out of 43 tumors collected when the mice were administered doxycycline (hereon referred to as the 'primary' tumors) and 38 tumors that recurred or continued to grow after doxycycline withdrawal (hereon referred to as the 'Myc-independent' tumors; Figure 1a) . As a starting point of our analyses, we first confirmed that MYC expression was tightly controlled by doxycycline, by comparing MYC pathway activity using a Myc gene expression signature that had previously been generated in our lab and validated on independent mouse data sets (Huang et al., 2003; Bild et al., 2006; Gatza et al., 2010) . The advantage of utilizing gene expression signatures is the ability to assess gene patterns represented by a collection of genes related to MYC expression thus offering an assessment of MYC activity rather than just MYC expression. Pathway analysis of the primary tumors showed high MYC activity when mice were still on doxycycline, as shown in Figure 1c . MYC pathway activity was diminished in recurrent tumors collected when the mice were off doxycycline with the exception of two tumors (238A and 279A). Not surprisingly, both of these tumors did not regress to a nonpalpable state following removal of doxycycline, consistent with continued MYC function. Although we have not looked further into the underlying cause of constitutive high MYC activity in these tumors, we eliminated the possibility that endogenous c-Myc could be spontaneously activated. Earlier work on recurrent mammary tumors from MTB/TOM mice showed endogenous c-Myc levels comparable to those found in carcinogen-induced mammary adenocarcinomas (Boxer et al., 2004) . Podsypanina et al. (2008) however, had previously reported the acquisition of spontaneous somatic mutations in the rtTA transgene cDNA resulting in the enhanced ability of the rtTA to bind and constitutively activate the tetO promoter. We speculate that this may be a possible explanation for the high MYC activity we observe in these tumors.
Numerous studies have documented the synergistic actions of MYC and mutant Kras2 in mammary tumorgenesis (D'Cruz et al., 2001; Boxer et al., 2004; Podsypanina et al., 2008; Andrechek et al., 2009) . In principle, Ras activation could be an explanation for the development of Myc independence in a fraction of the tumors. To address this possibility, we sequenced the mutational hot spots in Kras2 (codons 12, 13 and 61 of exons 1 and 2). Sequence analyses reveal mutations in Kras2 in 49% of Myc-independent tumors analyzed ( Table 1) . Kras2 mutations were found in 35% of tumors that regressed to a nonpalpable state and 44% of tumors that showed some signs of regression but were still palpable. Among tumors that showed no signs of regression after removal of Myc, 80% of these tumors carry mutations in Kras2. These observations are consistent with previous work, suggesting a role for mutant Kras activity in promoting tumorgenesis (D'Cruz et al., 2001; Boxer et al., 2004; Podsypanina et al., 2008; Andrechek et al., 2009) . A majority of the mutations were observed in codon 12 with the exception of two tumors with mutations in codon 61. The amino acid changes in the mutations varied with a majority of them being a glycine to aspartic acid mutation. Mutations in Kras2 that were observed in the primary tumor samples were also observed in the recurring tumors thus confirming that the tumors represent bona fide recurrences rather than de novo neoplasms. Four of the primary tumors (B114-4, B169, B179 and B233) that did not initially have mutations in Kras2 eventually acquired mutations in Kras2 when the tumors were collected upon necropsy. Among these four tumors, B179 and B233 regressed to a point when the tumor was no longer palpable. B114 showed some extent of regression but was still palpable and B169 showed no signs of regression upon removal of doxcycline. Our results suggest that although Kras mutation status initially has a role in Myc-independent growth, additional genetic alterations have to also be involved because all tumors eventually thrive independent of MYC expression regardless of Kras mutation status.
Cluster analysis segregate mouse mammary tumors that escape dependence on Myc The Myc-induced mammary tumors from the MTB/ TOM mouse model, although initiated by one oncogenic event, showed variable responses to withdrawal of Myc expression likely reflecting additional alterations acquired in the tumors. To determine whether differential To further characterize the mammary tumors we obtained from the MTB/TOM mouse model, we performed an unsupervised clustering again with tumors we previously characterized from a mouse model that constitutively expressed Myc (MMTV-MYC). Our prior work has described considerable heterogeneity in tumors from this MMTV-Myc mouse model as distinct gene expression patterns that correlated with distinct histological subtypes (Andrechek et al., 2009) . Mammary tumors with papillary and microacinar histological types clustered in a group together apart from the EMT/ squamous tumors. An EMT tumor signature that was generated from this data was shown to identify human breast tumors that were likely to metastasize. As shown in Figure 2b , cluster analysis revealed a majority of the MTB/TOM primary tumors clustered most closely with the previously characterized microacinar tumors whereas the Myc-independent tumors primarily clustered with the previously characterized EMT and squamous tumors. Interestingly, in our prior classifications of mouse mammary tumors from our MMTV-Myc mouse model, we also observed a loss of Myc pathway activity in tumors that had progressed toward an EMT phenotype (Andrechek et al., 2009 ).
Myc-independent tumors acquire an EMT phenotype
Previous studies with Her2/neu-induced mammary tumors have observed that tumors recurring independent of Her2/neu transgene expression generally exhibited EMT-type histologies (Moody et al., 2005) . The unsupervised clustering analysis presented in Figure 2b provides evidence that the Myc-independent tumors are genetically distinct from the primary tumors and cluster with tumors that exhibit an EMT/squamous phenotype. To further confirm that the distinction in gene patterns reflects acquired genetic heterogeneity that allow tumors to become more resilient and escape Myc dependence rather than mere differences resulting from the absence of a Myc signature, we set out to investigate evidence for EMT in the MTB/TOM tumors. Loss of E-cadherin expression has been considered to be a fundamental event in EMT (Thiery, 2002; Thiery et al., 2009) . Examination of probe expression from the microarray data reveal downregulated E-cadherin expression in a subset of our Myc-independent tumors compared with the primary tumors. Further analysis revealed an inverse correlation with Snail expression, consistent with numerous reports that have proposed Snail to function as a transcriptional repressor of E-cadherin (Thiery, 2002; Thiery et al., 2009;  Figure 3 ).
We performed a histological analysis to confirm an EMT phenotype in the Myc-independent tumors. Microscopic examination of hematoxylin and eosin stained mouse mammary tumor samples from the MTB/TOM mouse revealed the primary tumor samples to be predominantly of the microacinar and large blue cell type whereas the Myc-independent samples were a mixture of large blue cell, squamous, papillary and spindle cell type that are often characteristic of EMT. The EMT-like histology pattern was not observed among the primary tumor samples we examined (Supplementary Table 1 and Figure 4a ). A number of markers have been established to provide a definitive characterization of EMT tumors (Damonte et al., 2007; Radaelli et al., 2009; Cardiff, 2010) . Immunohistochemical analysis for some of the most relevant EMT markers unequivocally confirmed the acquisition of EMT phenotype in Myc-independent tumors from MTB/TOM mice. The neoplastic spindle cell component found in these tumors showed co-localized expression of both epithelial and mesenchymal markers such as cytokeratin 8/18 and vimentin. In contrast, cytokeratin 19 was found only in the glandular epithelium. Possibly reflecting downregulation of E-cadherin occurring during EMT, the progressive loss of a clear glandular architecture and the acquisition of a spindle cell morphology were also consistently accompanied by a gradual decrease in E-cadherin expression along the cell membrane. Additionally, transforming growth factor-b2 and N-cadherin, other two markers typically associated with the promotion and progression of EMT, were found to be to be expressed in both glandular and spindle elements (Figure 4b) . Collectively, our results show significant histological and genetic features indicative of a more mesenchymal phenotype in the mycindependent cells.
MYC-independent growth has features of cancerinitiating cells
A variety of studies has proposed a role for so-called tumor-initiating cells as a component of the underlying mechanism of tumor recurrence and the acquisition of drug resistance. These cells generally display characteristics of EMT, show mammosphere-forming and higher tumor seeding capabilities, and are identified by B53top   B55  B61  B67  B82  B114-3  B114-4  B163  B165  B169  B172  B175-2  B176  B179  B207-2  B207-3  B226  B243  B251  B267-1  B270  B272  B276  B279  B280  B308-1  B308-2  B308-4  B233  B239 Immunohistochemical profile of a Myc-independent EMT tumor. Cytokeratin 8/18 is observed in both glandular and spindloid epithelial elements whereas cytokeratin 19 is observed only in the glandular epithelium. Vimentin is expressedin the spindle epithelium, which also contains cytokeratin8/18. Transforming growth factor-b2 is found in both glandular and spindle elements. E-cadherin is detected only in the membrane of glandular elements and is barely detectable in the scattered spindle cells. N-cadherin is found in some of the glandular epithelial cells and is prominent in the cytoplasm of the spindle cells. Space bar, 100 mm. ). These 'tumor-initiating' cells are thought to be resistant to therapy and may, therefore, contribute to cancer relapse (Nicolini et al., 2010; Iseri et al., 2011) . Given that an escape from Myc-dependence in general parallels a form of resistance to blockade of an oncogenic pathway similar to the acquisition of resistance to targeted therapy in human cancers, we sought to explore the extent to which the recurrent tumors were comparable to 'tumor initiating' cells previously characterized from human breast cancers. For this analysis, we utilized data from human breast cancers that have been flow-sorted for expression of the CD44 þ /CD24À/low cell surface marker (GSE7513; Al-Hajj et al., 2003) . We generated a gene expression signature and validated this signature on an independent data set (GSE6883; Supplementary  Figure 2) . We then examined the probability of this CD44 þ /CD24À/low gene signature in the primary and Myc-independent mouse mammary tumors. As shown in Figure 5a , tumors that have escaped MYC dependence had a statistically significant higher probability of exhibiting the CD44 þ /CD24À/low gene signature. Additionally, an analysis of our primary tumors showed a higher probability of the CD44 þ /CD24À/low gene signature in tumors that do not regress to a nonpalpable state in response to initial Myc removal versus tumors that regressed to a nonpalpable state (Figure 5b) . Collectively, these results showed MYC-independent growth is generally associated with a higher CD44 þ /CD24À/low gene signature probability and suggests that MYC-independent growth may be acquired through mechanisms reminiscent of how human tumors recur and acquire drug resistance.
Discussion
Perhaps the largest challenge facing the effective treatment of cancer, including breast cancer, is the substantial heterogeneity and complexity that is evident in these disease states. Breast cancer is not one disease but rather a multitude of disorders with distinct etiologies. This can be seen in the variation evident in primary tumors that defines response to therapies as well as differential prognosis. It can also be seen in the recurrence of disease following initial therapy that most often is then associated with mortality. Elucidating the heterogeneity that permit tumor cells to escape blockade of a dominant oncogenic pathway, survive in a latent state and eventually reestablish malignant growth is thus of fundamental importance to making progress toward the goal of effective treatments and improved disease outcomes. The ability to use a mouse genetic model as a means to study these events, particularly the distinctions among primary tumors that define response to therapy and subsequent disease progression, is a key opportunity to better understand the human disease. We suggest that the observations we describe here, that provide clear evidence for heterogeneity and complexity within a mouse model reflecting events seen in the human disease, is one such opportunity.
Although the mouse mammary tumors studied here were initiated by a single oncogenic event, clearly substantial heterogeneity is present in the primary tumors that determined the response to Myc withdrawal and the likelihood for progression to the Myc-independent state. The withdrawal of Myc expression, as enabled in this model, is an accurate mimic for a Mycspecific drug. Apparently, some of the tumors are more reliant on the action of Myc and thus their growth is subdued by the inhibition of Myc function but others are not. This variation, that determines the outcome of the 'Myc therapy', mirrors similar situations in the treatment of human cancers where for instance there is variation in the response to specific chemotherapy regimens on breast cancers. Consistent with previous findings, we have observed here that Ras activating mutations have a role in perpetuating tumor viability in the absence of Myc in a large fraction of tumors analyzed. Despite the clear evidence of a bona fide role for aberrant Ras activity in tumor progression, however, it is also evident that other factors have to be involved in the small subset of tumors that lack Ras activating mutations but also acquire Myc-independent growth. Given the growing interest of an EMT phenotype and its relevance to more invasive human cancers, mouse models that exhibit evidence of EMT can serve as good models for investigation the genetic events underlying the progression of human cancers to a more advanced stage. As such, our prior work has provided evidence that an EMT phenotype from MMTV-Myc mouse mammary tumors is associated with increased metastatic potential (Andrechek et al., 2009) . Our work provides novelty in that we have assessed gene profiles of these tumors and have found significant differences between the primary and Myc-independent tumors from the same mouse. We have also followed up on our observations with a histological analysis to confirm the EMT phenotype. These observations are consistent with prior studies that have documented evidence of the EMT phenotype in other genetically engineered mouse models (Damonte et al., 2007; Radaelli et al., 2009; Cardiff, 2010 Figure 5 (a) The probability of the CD44 þ /CD24À/low gene expression signature is compared between the primary and Mycindependent samples. (b) The probability of the CD44 þ /CD24À/ low gene expression signature is compared between primary samples that initially regressed to a nonpalpable state versus primary samples that did not regress to a nonpalpable state. mammary tumors escape oncogene dependence, and the extent to which these tumors parallel the EMT phenotype associated with increased potential for invasion and metastasis observed in human tumors, however, still remain a conundrum to be investigated with future work.
Recent work has connected EMT to the emergence of cancer stem cells (Mani et al., 2008) . Consistent with EMTlike features and the propensity for more aggressive tumor growth, a higher probability of the CD44 þ /CD24À/low gene signature was associated with MYC-independent growth. Tumorgenic breast cancer cells that express high levels of CD44 and low CD24 in humans have been proposed to be resistant to chemotherapy and are thought to be responsible for cancer relapse (Creighton et al., 2009) . We emphasize that although these results do not suggest that our recurrent tumors are cancer-initiating cells, these observations do suggest that the Myc-independent tumors share properties of tumor-initiating cells and are indicative of cells that are more robust and resistant to cell death. These cells may be acquired through a clonal evolution model of cancer where various combinations of mutations are accumulated in certain cells over a period of time rendering them more fit to survive and drive tumor progression (Campbell and Polyak, 2007) . Primary samples that did not regress after withdrawal of MYC expression were more likely to exhibit characteristics of the CD44 þ /CD24À/low phenotype. These results suggest CD44 þ /CD24À/low features may be a good predictor of the extent to which a tumor has escaped MYC dependence in this mouse model and further suggests this model to be good system for developing combination therapeutic strategies to target cells that are resistant to the ablation of one oncogenic pathway. Furthermore, studies by Creighton et al. (2009) . have alluded to the similarities between CD44 þ /CD24À/low and mammosphere-forming cells to human breast cancers of the 'claudin low' type, previously characterized by Herschkowitz et al., 2007. These findings highlight the value of further defining the potential of this MTB/TOM mouse model in studying the molecular complexity underlying specific groups of human cancers.
Finally, an area of research that is becoming increasingly more intriguing is the mechanisms underlying the phenomenon of oncogene addiction and how some tumors escape this addiction. What is evident in the studies we present here is the degree of heterogeneity acquired in tumors that evolve to thrive independent of expression from the oncogene-initiating event. The value in this determination is the extent to which the heterogeneity itself is a model of human disease and thus provides an opportunity for further dissection of this heterogeneity with the goal of working toward personalized therapeutics in human cancer.
Materials and methods
Animals
MTB/TOM mice were obtained from Lewis A Chodosh at the University of Pennsylvania. Animal use and husbandry were in accordance with Institutional and Federal guidelines. Bitransgenic animals were induced by administering doxycycline (2 mg/ml; Sigma, St Louis, MO, USA) in their drinking water, which was replaced weekly. Animals were monitored for the tumor growth weekly.
Tissue collection
A biopsy was taken when mammary tumors were B1 cm 3 . Mice with recurring tumors or tumors that did not regress were euthanized when tumors were B41 cm 3 . Tumor tissues collected for RNA extraction were flash frozen in liquid nitrogen. Tumor tissues collected for histology were fixed in formalin and then were processed for routine histology at UC Davis Center for Comparative Medicine (see below).
Kras2 mutation analysis cDNA was generated and PCR amplified for sequencing using titanium one step RT-PCR (Clontech, Mountain View, CA, USA). DNA fragments from Kras2 were gel purified and sequence analysis was performed by Duke DNA Sequencing Facility (Durham, NC, USA).
Microarray analysis
Flash frozen RNA samples from mouse tissue were purified using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) after roto-stator homogenization and submitted to the Duke Microarray facility for hybridization to Affymetrix Mouse Genome 430A 2.0 array platforms. The resulting CEL files were normalized by Robust Multi-Array (RMA) or MicroArray Suite using Affymetrix Expression Console. MicroArray Suite normalized files were additionally log 2 transformed. The RAW. CEL files have been deposited into the Gene Expression Omnibus database under the accession number GSE22406.
Unsupervised cluster analysis
Unsupervised clustering was performed with the publicly available Cluster 3.0 software (Tokyo, Japan). Using the SD function under the 'filter' tab, genes were filtered down to B1000 genes. Under the 'adjusted' tab the option to center genes and center arrays was checked. Under the 'hierarchical' tab, the option to cluster genes and arrays were checked and average linkage was chosen. The results were visualized with JavaTreeView, a publicly available software supplied by Alok Saldanha (http://jt reeview.sourceforge.net/). Matlab (MathWorks, Natick, MA, USA) was then used to generate a color heat map of the results.
Statistical analysis of pathway predictions
The statistical methods for pathway analysis have been thoroughly described but are reiterated here for clarification (Huang et al., 2003; Bild et al., 2006; Gatza et al., 2010) . The following explanation is from Gatza et al., 2010 . In our pathway analysis, a signature represents a group of genes that collectively exhibit a consistent pattern of expression. This signature enables a distinction between two phenotypes. A metagene representing a group of genes that collectively demonstrate a consistent pattern of expression for a specific phenotype is identified from the training data (phenotype A versus B). Each signature summarizes its constituent genes as a single expression profile and is derived from the first principal component of that gene set. This factor corresponds to the largest singular value as determined by singular value decomposition. Bayesian methods are then used to estimate binary probability regression models based on a given set of expression vectors (values across metagenes) derived from the training data. Application of these models to an independent validation data set enables the evaluation of predictive probabilities of each of the two phenotypic states for each sample in the validation data set. In these analyses, gene selection and identification is based solely on the training data. Metagene values are computed using the principal components of the training data ensuring reproducibility of the signature irrespective of the composition of the validation data set. Bayesian fitting of binary probability regression models to the training data enable assessment of the relevance of the metagene signature in within-sample classification as well as estimation and uncertainty assessment for the binary regression weights. This results in the mapping of metagenes to probabilities of relative pathway status. Evaluation of independent tumor or cell line samples results in the prediction of relative pathway status generating estimated relative probabilities, and associated measures of uncertainty, of activation or deregulation for each sample in the validation data set.
To ensure that over-fitting does not occur in the generation of each signature, a leave-one-out cross validation was performed for each set of training data to examine the stability and predictive capabilities of our model. In this analysis, each sample is left out, one at a time, of the data set and the model was refitted (both the metagene factors and the partitions used) using the remaining samples. The software for this analysis can be downloaded from http://www.duke.edu/ Bdinbarry/BINREG/.
Pathway predictions for MTB/TOM mouse mammary tumors
The procedures for the generation of training data followed by predictions of pathway activity are described below.
Analysis of Myc pathway activity. The Myc training data were generated from human mammary epithelial cells infected with recombinant adenoviruses Ad-c-Myc or Ad-green fluorescent protein at equivalent multiplicity of infections. RNA was extracted from these cells and hybridized to Affymetrix U133 microarrays. RAW.CEL files were MicroArray Suite 5 normalized using Affymetrix Expression Console Version 1.1 and log 2 transformed. The Myc training data are provided in the Supplementary Information as 'myc_train_mas5log2' (Huang et al., 2003; Bild et al., 2006; Gatza et al., 2010) . Given that the Myc training data have already been validated on mouse samples previously, we did not validate this training data on additional mouse data here. In our MTB/TOM mouse data, mouse probe IDs from the 430A.2 microarray chip were converted to human U133 probe IDs using Chip Comparer and File Merger and the probability of Myc pathway activity was assessed using BINREG2, which can be downloaded at http://www.duke.edu/ Bdinbarry/BINREG/. The following parameters were used as follows: 500 gene/2 metagenes/Shift scale norm/quantile norm/ data are already logged/1000 burn in/5000 iterations. Numerical values representing probability of pathway activity is represented in a color map generated using Matlab.
Generation of a CD44 þ /CD24À/low gene signature and analysis of data. Generation of CD44 þ /CD24À/low training data: The CD44 þ /CD24À/low training data were generated from Gene Expression Omnibus data set GSE7513. RAW.CEL files were RMA normalized using Affymetrix Expression Console Version 1.1. This file is provided in the Supplementary Information as 'CD44.CD24_train_RMA'. In the 'CD44.CD24_train_RMA' file, '0' represents unsorted cells and the columns designated as '1' represents CD44 þ /CD24À/sorted cells. The file was loaded onto BINREG2, which can be downloaded at http:// www.duke.edu/Bdinbarry/BINREG/ for binary regression analysis. The following parameters were chosen in BINREG2 as follows: 400 genes/3 metagenes/1000 burn in/5000 iterations. The metagene scores for the training data are included in the Supplementary Information as 'Predicted Pathway Probabilities-Training.CD44 þ CD24À(GSE7513).'
Converting mouse Affymetrix probe IDs to human probe IDs for analysis and merging of data sets Mouse 430A 2.0 mouse probe IDs from the MTB/TOM data were converted to human U133 probed IDs using Chip Comparer http://chipcomparer.genome.duke.edu/ and File Merger http://filemerger.genome.duke.edu/. The GSE7513, GSE6883 and MTB/TOM data were then normalized again and merged using the Bayesian Factor Regression Model (Carvalho et al., 2008; Lucas et al., 2009) to remove technical variation between data sets.
Validation of CD44 þ /CD24À/low signature on publicly available mouse data The RAW CEL files representing sorted and unsorted cells were downloaded from the data set with the gene accession number GSE6883. The data were RMA normalized using Affymetrix Expression Console Version 1.1 and merged and normalized to GSE7513 as described above. The result of this validation set is reported by BINREG2 as an output file denoted as validation.txt. Columns of output are as following:
(1) the column number in input file, (2) phenotype call, (3) average probability, (4) and (5) Predicting CD44 þ /CD24À/low pathway activity in MTB/ TOM tumors The data were RMA normalized using Affymetrix Expression Console Version 1.1. Mouse Affymetrix probe IDs were converted to human Affymetrix probe IDs as described above. Analysis in BINREG2 was performed using the parameters described above to generate the training data. The result of this validation set is reported by BINREG2 as an output file denoted as validation.txt. Columns of output are as following:
(1) the column number in input file, (2) phenotype call, (3) average probability, (4) and (5) upper and lower limits of the credible interval, (6) metagene score. The results are provided in the Supplementary Information as the 'Predicted Pathway Probabilities-MTBTOM.CD44 þ CD24À(GSE7513)' and 'Predicted Pathway Probabilities-MTBTOM (primaries_ only). CD44 þ CD24À(GSE7513)' file.
Comparison of predicted CD44 þ /CD24À/low probabilities Predicted probabilities were graphed on Graph Pad Prism 4.0 (Graph Pad Software, Inc., La Jolla, CA, USA). A two-tailed t-test was used to determine statistical significance of the comparisons between 'primaries' versus 'Myc-independent' samples and 'pegressed' versus 'no regression' as shown in Figure 5 .
Immunohistochemistry
All immunohistochemistry was performed analyzed at UC Davis Center for Comparative Medicine's Mutant Mouse Pathology Laboratory. In brief, tissue sections were cut B4 mm thick. Immunohistochemical staining was performed using Vectastain Elite ABC kit (Vector Labs, Burlingame, CA, USA). The following antibody dilutions were used as follows: vimentin, 1:1000 (Epitomics, Burlingame, CA, USA); cytokeratin 8/18, 1:8000 (Fitzgerald, Acton, MA, USA); cytokeratin 19, 1:1000 (Epitomics); transforming growth factor-b2, 1:1600 (Abcam, Cambridge, MA, USA); E-cadherin, 1:1200 (Abcam) and Ncadherin 1:800 (Epitomics). All antibodies were incubated at room temperature overnight at the indicated dilutions and 3,3 0 -diaminobenzidine staining was performed following the manufacturer's protocol. Hemotoxylin and eosin staining was performed using the standard procedures. Images of all slides were captured at the University of California, Davis Center for Genomic Pathology using the Aperio ScanScope XT at 50 000d.p.i. with the Â 20 objective, stored in a customized version of Spectrum 10.1.5.2028 (Aperio Technologies, Carlsbad, CA, USA) database and viewed using the Aperio ImageScope v11.0.2.716. Fields selected for publication were captured in TIFF file format at Â 20 using the 'snap shot' tool. Each image contained a 'ruler tool' scale bar that was maintained through the image processing in Photoshop for publication. The images were cut, pasted and sized in Photoshop to meet the page design and publisher's specifications.
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